There is no true subscription service for modafinil in the conventional sense, and the reason comes down to its legal status. In the United States, modafinil is a Schedule IV controlled substance, which means it requires a valid prescription from a licensed healthcare provider and carries federal restrictions on how refills are issued. Automatic recurring delivery, the way you might subscribe to a supplement or a razor, is not legally available for modafinil through any licensed pharmacy.
What Refills Actually Look Like
The closest thing to a recurring delivery arrangement is what licensed telehealth providers and pharmacies offer to patients with an ongoing prescription. Many providers require periodic follow-up before issuing additional refills, though some allow a 90-day supply once a patient has demonstrated consistent, stable use. If a telehealth provider approves your prescription, it can be sent electronically to a licensed pharmacy for home delivery, which in practice can feel like a recurring arrangement. Services such as Klarity Health and SleepMed connect patients with licensed providers for telehealth consultations and, if appropriate, prescriptions that are filled and shipped to the patient’s door.
The key distinction is that each refill still requires clinical oversight. A provider must confirm the prescription is still appropriate before it is renewed. No legal U.S. pharmacy can provide open-ended, automatic recurring shipments without a valid prescription and authorized refills.
The International Gray Market
Outside the licensed prescription route, a separate market of overseas online pharmacies operates largely from India and other countries where modafinil is not classified as a controlled substance and can be sold without a prescription. Vendors like ModafinilXL and ModafinilUSA ship generic modafinil internationally and offer bulk pricing that functions like a repeat-order model, with discounts for larger quantities, free reshipping if customs seizes a package, and loyalty incentives. These vendors do not use the word “subscription” but the per-order model is designed for repeat customers.
Ordering this way involves legal and quality risk. In the U.S., importing a controlled substance without a prescription violates federal law. While customs seizure of personal-use quantities is the more common outcome rather than prosecution, the FDA and DEA do not sanction these purchases. Multiple analyses of online pharmacies have found variable quality control and regulatory noncompliance among sites selling modafinil without a prescription, and product purity cannot be independently verified.
Who Qualifies for a Legal Prescription
The FDA approves modafinil for three conditions: narcolepsy, obstructive sleep apnea with residual daytime sleepiness, and shift work sleep disorder. A licensed provider can also prescribe it off-label for other conditions at their discretion. Telehealth platforms authorized to prescribe Schedule IV controlled substances can conduct the initial evaluation via video consultation. Under DEA rules extended through December 31, 2026, providers can prescribe controlled substances via telemedicine without a prior in-person visit, provided certain conditions are met.
A prescription is not guaranteed after a consultation. Providers make independent clinical decisions, and a diagnosis of a qualifying condition is typically required.
What to Expect From Legal Home Delivery
If you qualify and receive a prescription, most licensed U.S. pharmacies, including mail-order options, can ship modafinil to your home. Domestic delivery typically takes three to four business days. Generic modafinil is available at a significantly lower cost than the brand-name version, Provigil, and insurance may cover it, though prior authorization is often required.
HSA and FSA funds are generally eligible for both the telehealth consultation and the prescription cost when using providers that don’t accept insurance directly.
The Bottom Line
If you have a qualifying condition, a recurring prescription with home delivery through a telehealth provider is the legal path closest to a subscription model. If you’re outside that category or looking for something more frictionless, no compliant service currently exists that allows automatic, recurring delivery without clinical oversight at each refill.
Sources
- U.S. Drug Enforcement Administration. (1999, January 27). Schedules of controlled substances: Placement of modafinil into Schedule IV (Vol. 64, No. 17). Federal Register. https://www.federalregister.gov/documents/1999/01/27/99-1791/schedules-of-controlled-substances-placement-of-modafinil-into-schedule-iv
- U.S. Drug Enforcement Administration. (2026, January 29). Controlled substances alphabetical order (Orange Book). DEA Diversion Control Division. https://www.deadiversion.usdoj.gov/schedules/orangebook/c_cs_alpha.pdf
- U.S. Food and Drug Administration. (2022, December). Provigil (modafinil) prescribing information. Cephalon, LLC. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e16c26ad-7bc2-d155-3a5d-da83ad6492c8
- U.S. Drug Enforcement Administration & U.S. Department of Health and Human Services. (2025, December 31). Fourth temporary extension of COVID-19 telemedicine flexibilities for prescription of controlled medications. Federal Register. https://www.federalregister.gov/documents/2025/12/31/2025-24123/fourth-temporary-extension-of-covid-19-telemedicine-flexibilities-for-prescription-of-controlled
- U.S. Drug Enforcement Administration. (2025, December 31). DEA extends telemedicine flexibilities to ensure continued access to care [Press release]. https://www.dea.gov/press-releases/2025/12/31/dea-extends-telemedicine-flexibilities-ensure-continued-access-care
- U.S. Department of Health and Human Services. (2026, January 2). HHS and DEA extend telemedicine flexibilities for prescribing controlled medications through 2026 [Press release]. https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html
- Vanhee, C., Deconinck, E., George, M., et al. (2025). The occurrence of illicit smart drugs or nootropics in Europe and Australia and their associated dangers: Results from a market surveillance study by 12 official medicines control laboratories. Pharmaceuticals. https://pmc.ncbi.nlm.nih.gov/articles/PMC12193813/
- Therapeutic Goods Administration. (2025, October). Modafinil: Why “smart drugs” are not the brightest option. https://www.tga.gov.au/news/news-articles/modafinil-why-smart-drugs-are-not-brightest-option